Revvity, Inc. RVTY recently announced that its Revvity Signals Software business is launching Signals LabGistics, an AI-first solution designed to connect and orchestrate scientific workflows from early discovery through development and manufacturing. The offering aims to help pharmaceutical, biotechnology and specialty chemical companies coordinate complex processes, improve workflow visibility and facilitate technology transfer from research and development to manufacturing.
Signals LabGistics is expected to be available in the United States, Canada, Europe and Japan in December 2026.
Per management, scientific innovation depends more on the ability to coordinate people, systems and processes across each stage of development. Revvity Signals LabGistics connects these elements to help organizations advance new therapies and products with greater speed, consistency and confidence.
RVTY Stock Trend Following the News
RVTY stock has gained 0.4% since the announcement on Tuesday. Year to date, the stock has rallied 61.8% compared with the industry’s 8.6% growth and the S&P 500’s 12.2% rise.
Signals LabGistics could create additional growth opportunities for RVTY by expanding its software offering to organizations seeking greater efficiency across scientific operations. By addressing coordination challenges that can delay development and manufacturing, the solution may help Revvity attract customers looking to modernize laboratory processes and strengthen their digital infrastructure. Its compatibility with existing platforms could also ease adoption, while applications across multiple industries broaden the potential customer base and support demand for the company's software solutions.
RVTY currently has a market capitalization of $17.41 billion.
Image Source: Zacks Investment Research
More on the News
Signals LabGistics uses AI to convert natural-language instructions and standard operating procedures into coordinated scientific workflows. The solution is designed to address fragmented systems and manual handoffs that can slow research and development, particularly when transferring technologies from R&D to manufacturing. By connecting teams, processes and real-time data in a unified digital environment, it aims to improve coordination and support informed decisions.
The platform integrates with Revvity Signals Software and existing laboratory and manufacturing systems, with the flexibility to connect to additional platforms over time. Its multi-tier execution and real-time monitoring capabilities help teams track workflow progress, identify bottlenecks and improve the movement of information, samples and activities across departments.
Signals LabGistics is designed to operate within the broader Revvity Signals Software ecosystem while integrating with existing laboratory and manufacturing platforms. Its ability to extend into adjacent systems over time could help customers build connected scientific environments without requiring an immediate overhaul of their current infrastructure.
The platform also includes flexible compliance and quality capabilities tailored to different industry needs. Pharmaceutical and biotechnology organizations can use these features to support GxP compliance across connected workflows, while specialty chemical and materials science companies can seek operational improvements suited to their regulatory requirements.
Industry Prospects Favoring the Market
According to Grand View Research, the global laboratory informatics market is projected to reach $4.3 billion in 2026 and is projected to witness a CAGR of 4.9% through 2033.
Factors such as rising demand for laboratory automation, growing adoption of digital technologies across pharmaceutical, biotechnology and research laboratories, the need for efficient workflow and data management and increasing regulatory compliance requirements are driving market growth.
Other News
Revvity recently launched the GSP T1D 3plex kit, a fully automated, CE-IVDR-certified multiplex autoantibody detection solution in Europe. The kit is designed to support population-wide screening for children at risk of developing type 1 diabetes (T1D) before symptoms appear. The solution uses capillary dried blood spot (DBS) samples and is processed on Revvity’s GSP instrument, extending the company’s screening capabilities from newborn screening into early childhood.
Revvity entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company focused on human cell models and preclinical research solutions for metabolic diseases. The acquisition will bring HCD’s human pancreatic beta cell models into Revvity’s Life Sciences portfolio.
Revvity Inc. Price
Revvity Inc. price | Revvity Inc. Quote
RVTY’s Zacks Rank & Key Picks
Currently, Revvity carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are OPKO Health OPK, Globus Medical GMED and Intuitive Surgical ISRG.
OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Intuitive Surgical, currently carrying a Zacks Rank #2, reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.
Intuitive Surgical has a long-term estimated growth rate of 14.9%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.1%.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Revvity Inc. (RVTY): Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
OPKO Health, Inc. (OPK): Free Stock Analysis Report
Globus Medical, Inc. (GMED): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).